MAR 19, 2015 1:53 PM PDT

Study Reveals Treatment for Women with Breast Cancer Suffering Cognitive Difficulties

WRITTEN BY: Ilene Schneider
UCLA researchers have developed a program that could improve the day-to-day lives of women with breast cancer by addressing post-treatment cognitive difficulties, sometimes known as "chemo brain," which can affect up to 35 percent of women after their treatments.

An estimated one in eight women will develop invasive breast cancer in their lifetimes, and following treatment, a mental fogginess can prevent them from being able to concentrate, staying organized and completing everyday activities, such as sticking to a schedule or planning a family gathering.

The new study, led by breast cancer research pioneer and UCLA Jonsson Comprehensive Cancer Center member Dr. Patricia Ganz, builds upon her earlier research that found a statistically significant association between neuropsychological test performance and memory complaints among women with early stage breast cancer following treatment.

"We invited the women to participate in a research study that assigned them to early or delayed treatment with a five-week, two-hour group training session, where a psychologist taught them strategies to help them with their memory and maintaining their ability to pay attention to things," said Ganz, director of prevention and control research at the cancer center. "These are activities we call executive function and planning, or the things all of us do in order to organize our day."

Dr. Linda Ercoli, an associate clinical professor of health sciences at the UCLA Semel Institute for Neuroscience and Human Behavior, was responsible for the development of the cognitive rehabilitation intervention program and either delivered the training or supervised other clinicians who provided the group training sessions.

"We gave women exercises on, for example, how to remember a ‘to-do' list, remembering to buy items at the store, or planning a party and deciding what type of food should be served to guests," said Ercoli, a co-author of the study. "Participants were given real-life tasks to complete that would use these types of strategies to improve cognitive function."

The intervention program also included homework and practice activities that they would discuss at the weekly sessions. These exercises were designed to improve memory and cognitive function.

Women in the delayed group were offered the intervention after completion of their two-month follow-up testing and this occurred when the researchers had enough women to form a group to provide them the intervention.

All of the women who participated in the study, whether they received the intervention early or at a delayed time point, completed questions about their mood and mental functioning. The women also had detailed neurocognitive testing three times: before learning which group they would be in, immediately after the end of the five weeks of training and then again two months later. Most of the women also had resting EEG (brain wave) testing to see if this could measure changes in how the women fared throughout the study.

Ganz and Ercoli found that the 32 women in the early intervention group reported improvement in memory complaints and test functioning, while the 16 women in the delayed intervention control group did not improve in either their cognitive complaints or test performance. The intervention group participants showed continued improvement two months after completion of the rehabilitation program.

"The brain wave pattern in the intervention group actually normalized," Ganz said. "We hope that this might be an effective biologic way to assess the cognitive effects of cancer treatment in the future."

The next steps are for other researchers to test this cognitive rehabilitation program in larger numbers of patients, and potentially to develop strategies to provide intervention much earlier in the course of breast cancer treatment to either prevent difficulties or hasten recovery.

"This study will be added to the growing body of literature demonstrating the validity of patient complaints," Ganz said. "Furthermore, the intervention results provided important encouragement that these complaints can improve with appropriate training."

Source: UCLA
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
JUN 14, 2021
Cell & Molecular Biology
Can An Omega-3 Fatty Acid Destroy Tumors?
JUN 14, 2021
Can An Omega-3 Fatty Acid Destroy Tumors?
The body needs fatty acts for a variety of functions, and the health benefits of taking fatty acid supplements have long ...
JUL 18, 2021
Cancer
Light Alcohol Use Linked to Higher Cancer Risk
JUL 18, 2021
Light Alcohol Use Linked to Higher Cancer Risk
Moderate alcohol use is linked to a substantially higher risk of several forms of cancer, including breast, colon, and o ...
AUG 19, 2021
Cancer
Age of Colorectal Cancer Diagnosis Does not Affect Tumor Growth
AUG 19, 2021
Age of Colorectal Cancer Diagnosis Does not Affect Tumor Growth
Early-onset colorectal cancer progresses in the same way as average onset colorectal cancer. The corresponding study was ...
SEP 16, 2021
Technology
Scientists Create Tiny Replicas Of The Pancreas To Study New Drugs
SEP 16, 2021
Scientists Create Tiny Replicas Of The Pancreas To Study New Drugs
Pancreatic cancer it’s often hard to diagnose in its early stages, resulting in patients having more advanced canc ...
SEP 21, 2021
Drug Discovery & Development
Lifesaving TheraSpheres - glass microbeads can target and destroy colorectal tumors
SEP 21, 2021
Lifesaving TheraSpheres - glass microbeads can target and destroy colorectal tumors
The innovative medical device manufacturer Boston Scientific recently showed success in treating patients with ...
SEP 23, 2021
Drug Discovery & Development
The FDA approves the first and only oral treatment for a certain non-small cell lung cancer.
SEP 23, 2021
The FDA approves the first and only oral treatment for a certain non-small cell lung cancer.
Last week, the United States Food and Drug Administration (FDA) granted approval for the first oral therapy to ...
Loading Comments...